Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials
Study context
- Population
- Patients with rheumatoid arthritis (RA) in phase 2–4 randomized controlled trials (RCTs) of tocilizumab (TCZ) or JAK inhibitors (JAKi) vs controls (TNFi or placebo); six databases searched until May, 2024
- Participants
- 21,432 patients18 RCTs
- Comparison
- JAKi or tocilizumab vs TNFi
- Outcome
- MACE
Methodological detailstraditional and Bayesian network meta-analysis, random effects, phase 2-4 RCTs, Cochrane risk-of-bias tool
- Traditional and Bayesian network meta-analysis
- Random effects
- Phase 2-4 RCTs
- Cochrane risk-of-bias tool
Pooled result
As reported in the abstract
Each group vs TNFiOdds ratio (95% CI)P value
JAKiBayesian PP15% of 61%
1.232(0.86–1.76)
P = 0.56- TCZ · Bayesian PP15% for major adverse cardiovascular events (MACE) of 11%
- 1.029 (95% CI 0.75–1.40); P = 0.86
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| All-cause deathJAKivs TNFiBayesian PP15% of 84% | 1.3903 (0.94–2.07) | P = 0.10 | |
| 0.512Odds ratio (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| All-cause deathTCZ vs TNFi · Bayesian PP15% for ACD of 25% | 1.072 (95% CI 0.78–1.48) | P = 0.67 |
Original publication
Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials. Semin Arthritis Rheum. Published 2 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →